TTY Biopharm Company Limited (TPEX:4105)

Market Cap	20.69B
Revenue (ttm)	6.50B
Net Income (ttm)	1.79B
Shares Out	248.65M
EPS (ttm)	7.19
PE Ratio	11.57
Forward PE	12.19
Dividend	4.20 (4.94%)
Ex-Dividend Date	Mar 27, 2025

Volume	1,428,624
Average Volume	938,521
Open	85.00
Previous Close	85.00
Day's Range	83.10 - 85.40
52-Week Range	66.20 - 85.40
Beta	-0.02
RSI	63.05
Earnings Date	Mar 13, 2026

About TTY Biopharm Company

TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan and internationally. The company operates through Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, and Other Business Unit segments. It offers oncology drugs under the Lipo-Dox, Lonsurf, UFUR, TS-1, Pexeda, Gemmis, Oxalip, Irino, Epicin, Tynen, Anazo, Folina, Thado, Andason, Ivic, Asadin, Leavdo, Painkyl, Megest, Episil, Otril, Zobonic, Yond...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1960
• Employees: 342
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4105

Financial Performance

In 2024, TTY Biopharm Company's revenue was 5.89 billion, an increase of 7.05% compared to the previous year's 5.51 billion. Earnings were 1.45 billion, an increase of 28.45%.